AnaptysBio, Inc. (NASDAQ:ANAB) had its price target boosted by Credit Suisse Group from $38.00 to $85.00 in a report released on Tuesday. Credit Suisse Group’s price objective points to a potential upside of 21.53% from the stock’s current price.
A number of other equities research analysts have also recently issued reports on the stock. JMP Securities boosted their target price on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a report on Tuesday. Royal Bank Of Canada began coverage on shares of AnaptysBio in a report on Thursday, September 14th. They set an “outperform” rating and a $40.00 target price on the stock. Zacks Investment Research raised shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a report on Wednesday, September 13th. Stifel Nicolaus reissued a “buy” rating and set a $35.00 target price on shares of AnaptysBio in a report on Tuesday, September 12th. Finally, Robert W. Baird began coverage on shares of AnaptysBio in a report on Monday, July 10th. They set an “outperform” rating and a $36.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $59.14.
AnaptysBio (NASDAQ:ANAB) opened at 69.94 on Tuesday. The stock has a 50 day moving average price of $37.36 and a 200 day moving average price of $37.36. The firm’s market cap is $1.42 billion. AnaptysBio has a 52-week low of $15.17 and a 52-week high of $74.00.
AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.29. The business had revenue of $7.00 million for the quarter, compared to the consensus estimate of $3.45 million. Equities analysts predict that AnaptysBio will post ($1.98) earnings per share for the current fiscal year.
In other news, major shareholder Holdings A/S Novo sold 356,300 shares of the business’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the completion of the transaction, the insider now directly owns 1,936,604 shares in the company, valued at approximately $40,862,344.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,133,940 shares of company stock valued at $24,223,316 over the last 90 days.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC purchased a new position in shares of AnaptysBio during the 1st quarter valued at $24,474,000. Artal Group S.A. grew its position in shares of AnaptysBio by 459.4% during the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $5,983,000 after purchasing an additional 205,310 shares in the last quarter. Marshall Wace North America L.P. purchased a new position in shares of AnaptysBio during the 1st quarter valued at $6,924,000. MARSHALL WACE ASIA Ltd purchased a new position in shares of AnaptysBio during the 1st quarter valued at $6,924,000. Finally, Vanguard Group Inc. grew its position in shares of AnaptysBio by 22.6% during the 2nd quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock valued at $4,931,000 after purchasing an additional 37,932 shares in the last quarter. Hedge funds and other institutional investors own 71.35% of the company’s stock.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
What are top analysts saying about AnaptysBio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AnaptysBio Inc. and related companies.